These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22172466)

  • 1. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature.
    Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M
    Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 3. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
    Feldmann G; Brossart P; von Lilienfeld-Toal M
    Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506
    [No Abstract]   [Full Text] [Related]  

  • 4. Interstitial lung disease associated with azacitidine use: a case report.
    Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
    Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylating therapy and autoimmunity in MDS: an enigmatic relationship.
    Kotsianidis I; Spanoudakis E; Nakou E; Miltiades P; Margaritis D; Tsatalas C; Tzouvelekis A; Oikonomou A
    Leuk Res; 2012 Apr; 36(4):e90-2. PubMed ID: 22230300
    [No Abstract]   [Full Text] [Related]  

  • 6. Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
    Turturro F; Leary C; Stephens J; Veillon D; Lowery-Nordberg M
    J Clin Oncol; 2010 Aug; 28(22):e380-1. PubMed ID: 20458054
    [No Abstract]   [Full Text] [Related]  

  • 7. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
    Almeida AM; Pierdomenico F
    Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
    Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
    Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine adverse effects in patients with myelodysplastic syndromes.
    San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.
    Tseng E; Alhusayen R; Sade S; Buckstein R; Prica A
    Br J Haematol; 2015 May; 169(4):461. PubMed ID: 25765235
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 14. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 15. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
    Lai SW; Huang TC; Ye RH; Wu YY
    Eur J Haematol; 2015 Mar; 94(3):273-6. PubMed ID: 24797511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
    Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
    Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of azacitidine: onset, duration, and treatment.
    Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
    Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
    Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.